Codexis

The article outlines the oligonucleotide synthesis market, covering synthesis technology, applications, industry players, market factors, recent developments, and global market overview. It highlights advancements in synthesis technology, the role of diagnostics, and the impact of COVID-19, alongside profiles of key companies and market segmentation by length, application, product, category, and type.

Caribou Biosciences (CRBU) appointed Sri Ryali as CFO, effective immediately. Ryali, with a background in finance at Codexis, Eiger BioPharmaceuticals, Aimmune Therapeutics, Onyx Pharmaceuticals, and Amgen, brings extensive experience to the role.

The global synthetic biology market was valued at USD 10.7 billion in 2021 and is projected to grow at a CAGR of 21.3% to reach over USD 74.7 billion by 2031, driven by advancements in biotechnology, applications in healthcare, agriculture, and energy, and demand for sustainable solutions. Key players include Bristol-Myers Squibb, Gevo, Inc., Life Technologies, and others. Challenges include regulatory issues, ethical concerns, high R&D costs, and technical challenges, while opportunities lie in sustainable solutions, personalized medicine, and bio-based products.

DelveInsight's 'Fabry Disease Pipeline Insight, 2024' report details 18+ companies developing 18+ therapies, including Venglustat, Pegunigalsidase alfa, and 4D 310, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, and Sangamo Therapeutics. The report covers pre-clinical to marketed phases, focusing on commercial and clinical assessments.

The white biotechnology enzymes market is projected to grow from $20.73 billion in 2024 to $56.37 billion by 2032, driven by advancements in biotechnology, demand for sustainable solutions, and expanding applications. Key trends include growth in bio-based industries, technological advancements in enzyme production, and regulatory support for sustainable technologies. Market drivers are the shift toward bio-based products, expanding application scope, and rising environmental concerns. Challenges include high production costs and regulatory barriers.

Artiva Biotherapeutics expands Board of Directors with Dr. Alison Moore, focusing on AlloNK® in autoimmune diseases. Initial data expected H1 2025. Cash reserves of $199.6 million fund operations through 2026.

White Biotechnology Market to grow at 10.1% CAGR, reaching nearly $865.50 Bn by 2030, driven by sustainable solutions and advancements in genetic engineering. North America and Europe lead in innovation, with challenges including high R&D costs and regulatory compliance. Key players include Amyris, BioAmber, and Novozymes.

Artiva Biotherapeutics appoints Alison Moore, Ph.D., as independent Board member, leveraging her 25+ years in biotech and pharma, focusing on cell therapy manufacturing.

The Oligonucleotide Synthesis market is experiencing rapid growth, driven by advancements in gene therapy, personalized medicine, and next-generation sequencing. Key applications include diagnostics, therapeutics, and data storage. Major players like Thermo Fisher Scientific and Agilent Technologies lead the market, with emerging technologies enabling complex oligonucleotide production.